Adaptive Biotechnologies Corporation

The conference will begin shortly. To raise and lower your hand during Q&A, you can dial star 1-1.

Good day, and thank you for standing by, and welcome to the fourth quarter and full year 2022 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Karina Caldavilla. Della, you may go ahead.

Karina Caldavilla Thank you, Justin, and good afternoon, everyone. I would like to welcome you to Adaptive Biotechnology's fourth quarter and full year 2022 earnings conference call. Earlier today, we issued a press release reporting adaptive financial results for the fourth quarter and full year of 22. The press release is available at www.adaptivebiotech.com. We are conducting a live webcast of this call and will be referencing to a slide presentation that has been posted to the investor section in our corporate website. During the call, management will make projections and other forward-looking statements within the meanings of federal security laws regarding future events and the future financial performance of the company. These statements reflect management's current perspective of the business as of today. Actual results may differ materially from today's forward-looking statements depending on a number of factors that are set forth in our public filings with the SEC and listed in this presentation. In addition, non-GAAP financial measures will be discussed during this call, and a reconciliation from non-GAAP to GAAP metrics can be found in our earnings release. Joining the call today are Chad Robbins, our CEO and co-founder, and Tycho Peterson, our chief financial officer. In addition, Harlan Robbins, adaptive chief scientific officer and co-founder, Nathan Soot, head of the MRG business, and Sharon Mancino, head of the immune medicine business, will be available for Q&A. With that, I'll turn the call over to Chad Robbins. Chad?